𝛼SK or Search

ENTITY

CStone Pharmaceuticals (2616 HK)

130

Analysis

Health Care • China

CStone Pharmaceuticals is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines for cancer patients. It has launched multiple innovative drugs, including sugemalimab, avapritinib, and pralsetinib, to address unmet medical needs in China and globally. The company was founded in 2015 and is headquartered in Suzhou, China.

more

Refresh

Exchange Announcement • 28 Sep 2026 21:25

Interim Report 2026

Exchange Announcement • 24 Sep 2026 18:30

Voluntary Announcement - Increase In Shareholding By Ceo And Executive Director Dr. Jianxin Yang By 496,000 Shares, With Accumulated Purchase Totaling 14,210,500 Shares

Exchange Announcement • 07 Sep 2026 08:06

Voluntary Announcement - The Company Included In Southbound Stock Connect

Exchange Announcement • 27 Aug 2026 19:32

Announcement Of Interim Results For The Six Months Ended June 30, 2026

Exchange Announcement • 21 Aug 2026 06:02

Voluntary Announcement - Nmpa Ind Approval For Cs5007 (Egfr/Her3 Bispecific Adc) In China

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x